Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
FiercePharma3d
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
The Pharma Letter8h
Gilead to withdraw Trodelvy indication in USA
Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...
Gilead upgraded to outperform by Leerink on PrEP outlook
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...
Daily1d
Gilead withdraws bladder cancer drug Trodelvy in US
Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...
Investing3d
Gilead retains Buy rating, stock target despite Trodelvy update
Despite the recent setback with Trodelvy's mUC indication, Gilead Sciences (NASDAQ:GILD) continues to demonstrate financial strength and market resilience. According to InvestingPro data ...
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in Metastatic Urothelial Cancer
Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...